Sg3 Management, LLC Tricida, Inc. Call Options Transaction History

Sg3 Management, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 15, 2023	SELL	$0.0 - $0.18 $0 - $900	-5,000 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$0.14 - $12.49 $11,620 - $1.04 Million	83,000 Added 1660.0%	88,000 $13,000
Q3 2022 May 15, 2023	SELL	$8.51 - $13.6 $706,330 - $1.13 Million	-83,000 Reduced 94.32%	5,000 $52,000
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $42,550 - $68,000	5,000 New	5,000 $52,000
Q4 2021 Feb 15, 2022	SELL	$4.19 - $9.56 $251,400 - $573,600	-60,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.56 - $4.64 $213,600 - $278,400	60,000 New	60,000 $278,000
Q2 2021 Aug 16, 2021	SELL	$3.95 - $5.41 $144,570 - $198,006	-36,600 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$4.52 - $7.8 $165,431 - $285,480	36,600 New	36,600 $194,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.